InflaRx N.V. (IFRX)
| Market Cap | 121.09M |
| Revenue (ttm) | 34,438 |
| Net Income (ttm) | -53.58M |
| Shares Out | 72.29M |
| EPS (ttm) | -0.80 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,082,350 |
| Open | 1.650 |
| Previous Close | 1.610 |
| Day's Range | 1.640 - 1.950 |
| 52-Week Range | 0.711 - 1.950 |
| Beta | 1.51 |
| Analysts | Strong Buy |
| Price Target | 7.00 (+317.91%) |
| Earnings Date | May 7, 2026 |
About IFRX
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company’s C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its u... [Read more]
Financial Performance
In 2025, InflaRx's revenue was 29,331, a decrease of -82.31% compared to the previous year's 165,789. Losses were -45.63 million, -0.93% less than in 2024.
Financial numbers in EUR Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for IFRX stock is "Strong Buy." The 12-month stock price target is $7.0, which is an increase of 317.91% from the latest price.
News
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
JENA, Germany, April 28, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”),...
InflaRx Reports New Mechanistic Data for Izicopan Supporting its Potential as a Best-in-Class C5aR Inhibitor
JENA, Germany, April 09, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Announces Participation in the Raymond James 2026 Biotech Innovation Symposium
JENA, Germany, March 31, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Highlights Clinical Activity of Vilobelimab in Pyoderma Gangrenosum in Late-Breaker Oral Presentation at 2026 American Academy of Dermatology Annual Meeting
Jena, Germany, March 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announce...
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readine...
InflaRx Announces Late-Breaker Oral Presentation on Vilobelimab Phase 3 Results in Pyoderma Gangrenosum at 2026 American Academy of Dermatology Annual Meeting
JENA, Germany, March 18, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
JENA, Germany, March 13, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx to Report Full Year 2025 Results on March 19, 2026
JENA, Germany, March 12, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced...
InflaRx Transcript: Leerink Global Healthcare Conference 2026
Restructuring has shifted focus to izicopan, an oral C5aR inhibitor, with promising phase II-A results in HS and expansion plans for AAV and CSU. Regulatory discussions aim to refine endpoints, and the company is funded into mid-2027 while seeking strategic partnerships.
InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference
JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Izicopan, a novel oral C5aR inhibitor, demonstrated rapid, deep, and sustained efficacy in HS and CSU, with a strong safety profile and superior pharmacokinetics compared to avacopan. Market opportunities in HS and ANCA-associated vasculitis are being actively pursued, with FDA discussions ongoing.
InflaRx Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
Izicopan demonstrates strong safety and efficacy signals, with rapid onset and unique benefits in HS. The company is advancing to a phase IIB trial, focusing on HS while exploring CSU and other indications, and has reduced costs to prioritize core programs.
InflaRx Announces Participation in February Investor Conferences
JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation
InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS) To broaden signal-finding activities for izicopan in ...
InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), s...
InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904
JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Positive data for an oral C5aR inhibitor in HS and CSU show rapid, durable efficacy and strong safety, with high-dose groups in HS performing best. The drug differentiates from Avacopan with faster, higher exposure and is advancing to phase 2b trials, supported by a strong cash position.
InflaRx Transcript: Status Update
INF904, an oral C5aR1 inhibitor, showed rapid, deep, and durable efficacy in HS and CSU, with a strong safety profile and best-in-class potential. High dose groups achieved significant reductions in lesions, pain, and disease activity, supporting further development in both indications.
InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU)
Phase 2a data support oral C5aR inhibitor INF904 as a potentially transformational and best-in-class immunomodulatory agent, indicating strong potential for efficacy and no safety signals of concern I...
InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria
Company expects to host a webcast to discuss the topline data on Monday, November 10 at 8:00 AM EST / 2:00 PM CET Company also expects to publish third quarter 2025 financial results on the same day p...
InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference
JENA, Germany, Oct. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
JENA, Germany, Sept. 12, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system (the “Company”),...
InflaRx Transcript: Cantor Global Healthcare Conference 2025
Upcoming data for a novel oral C5a receptor antagonist in HS and CSU could establish a new standard for efficacy and safety, with rapid onset and broad potential. Strategic partnerships and regulatory support are key to advancing both the antibody and small molecule programs across multiple indications.
InflaRx Announces Participation in September Investor Conferences
JENA, Germany, Aug. 21, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...
InflaRx Reports Second Quarter 2025 Financial Results and Provides Business Update
JENA, Germany, Aug. 07, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced ...